Clinical Trials Consortium Succeeds ADCS, Focuses on Prevention
The new ACTC network will establish streamlined recruitment and startup protocols to make trials more efficient.
ALL NEWS
6566 RESULTS
Sort By:
- Most Recent
- Most Commented
It’s Official: CSF Aβ42 Reference Standard Will Unify Assays
Certified reference material by which companies can calibrate assays is now available worldwide.
No Negativity, Please. Clinical Trial Leader Urges Focus on Learning, Progress
At recent CTAD conference, Rachelle Doody called on her colleagues to learn from failures and work together to support better drug evaluation studies.
First Genome-Wide Association Study of Dementia with Lewy Bodies
The GWAS confirms known associations, and hints at new ones. It suggests DLB is genetically distinct from AD or PD.
At Least We Know These Don’t Work: Negative Trials at CTAD
Null results ended the development of the neuroprotective drugs edonerpic and abeotaxane, the AMPA receptor modulator S47445, and the dietary formulation tricaprilin.
In the Running: Trial Results from CTAD Conference
Besides the big-gun antibodies and BACE inhibitors, smaller, lesser-known drug programs are inching their way through the clinical trials pipeline. As is often the case, Phase 1 seems encouraging.
Aβ, Tau Absolved of Causing Mild Cognitive Impairment in Parkinson’s
PET scans indicate no more AD pathology in PD-MCI than healthy controls, suggesting their cognitive decline results from other factors.
Elusive or Not, Aβ Oligomers Are in BioPharma Crosshairs
Ephemeral as they may be, these maligned peptides have become the targets of small-molecule and immunotherapies. Initial results of these efforts to catch and remove Aβ oligomers are trickling in.
Blood, the Secret Sauce? Focus on Plasma Promises AD Treatment
Phase 1 trial tests the rejuvenating effects of young blood, while albumin replacement may offer its own benefits.
Antisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a Trial
According to a press release by trial sponsor Ionis, therapy was well tolerated, but trial results have yet to be released.
Pimavanserin Trial Raises Hope for Treating Dementia-Related Psychosis
In a Phase 2 trial in nursing home residents with Alzheimer’s, this new drug mitigated symptoms safely, without detriment to cognition.
High-Dose Gantenerumab Lowers Plaque Load
Gradually raising the dose of this therapeutic antibody appears to ease the risk of brain inflammation.
Verubecestat Negative Trial Data: What Does it Mean for BACE Inhibition?
Presented at CTAD, BACE inhibitor’s efficacy and safety results in mild to moderate AD were encouraging to some clinicians, vaguely disquieting to others.
Don’t Be an Enrollment Loser: Throw Your Own Swab-a-Palooza!
Recruitment, recruitment, recruitment: Registries get creative in how they promote research engagement and fill prevention trials.
Cognitive Testing Is Getting Faster and Better
Who doesn’t dread hours of testing at a clinic? Innovation needed! Learn about frequent “burst” testing via mobile app, and a digital pen that captures more information than the old paper-and-pencil test.
Current Filters
No filters selected